BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 35289740)

  • 21. Oral Azithromycin and Response to Pulmonary Exacerbations Treated with Intravenous Tobramycin in Children with Cystic Fibrosis.
    Klingel M; Stanojevic S; Tullis E; Ratjen F; Waters V
    Ann Am Thorac Soc; 2019 Jul; 16(7):861-867. PubMed ID: 30874447
    [No Abstract]   [Full Text] [Related]  

  • 22. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.
    Tiddens HA; De Boeck K; Clancy JP; Fayon M; H G M A; Bresnik M; Derchak A; Lewis SA; Oermann CM;
    J Cyst Fibros; 2015 Jan; 14(1):111-9. PubMed ID: 25091537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polymicrobial infections and antibiotic treatment patterns for cystic fibrosis pulmonary exacerbations.
    Faino AV; Hoffman LR; Gibson RL; Kronman MP; Nichols DP; Rosenfeld M; Cogen JD
    J Cyst Fibros; 2023 Jul; 22(4):630-635. PubMed ID: 36849332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site.
    Schechter MS; Regelmann WE; Sawicki GS; Rasouliyan L; VanDevanter DR; Rosenfeld M; Pasta D; Morgan W; Konstan MW
    Pediatr Pulmonol; 2015 May; 50(5):431-40. PubMed ID: 25530325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009528. PubMed ID: 25741986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.
    Sanders DB; Solomon GM; Beckett VV; West NE; Daines CL; Heltshe SL; VanDevanter DR; Spahr JE; Gibson RL; Nick JA; Marshall BC; Flume PA; Goss CH;
    J Cyst Fibros; 2017 Sep; 16(5):592-599. PubMed ID: 28460885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral anti-pseudomonal antibiotics for cystic fibrosis.
    Remmington T; Jahnke N; Harkensee C
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD005405. PubMed ID: 27412131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of Pseudomonas aeruginosa eradication regimens on chronic colonization and clinical outcomes in pediatric patients with cystic fibrosis.
    Nayir Buyuksahin H; Yalçın E; Emiralioglu N; Hazırolan G; Ademhan Tural D; Ozsezen B; Sunman B; Guzelkas I; Dogru D; Ozcelik U; Kiper N
    Pediatr Int; 2022 Jan; 64(1):e15249. PubMed ID: 36321341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.
    Wagener JS; Rasouliyan L; VanDevanter DR; Pasta DJ; Regelmann WE; Morgan WJ; Konstan MW;
    Pediatr Pulmonol; 2013 Jul; 48(7):666-73. PubMed ID: 22888106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis.
    Palser S; Smith S; Nash EF; Agarwal A; Smyth AR
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012300. PubMed ID: 31845758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence, trends and outcomes of long-term inhaled antibiotic treatment in people with cystic fibrosis without chronic Pseudomonas aeruginosa infection - A European cystic fibrosis patient registry data analysis.
    Orenti A; Mei-Zahav M; Boracchi P; Lindblad A; Shteinberg M;
    J Cyst Fibros; 2023 Jan; 22(1):103-111. PubMed ID: 36045028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
    Smith S; Ratjen F; Remmington T; Waters V
    Cochrane Database Syst Rev; 2020 May; 5(5):CD006961. PubMed ID: 32412092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD006961. PubMed ID: 28628280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
    Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
    Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.
    Mayer-Hamblett N; Kronmal RA; Gibson RL; Rosenfeld M; Retsch-Bogart G; Treggiari MM; Burns JL; Khan U; Ramsey BW;
    Pediatr Pulmonol; 2012 Feb; 47(2):125-34. PubMed ID: 21830317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Greally P; Whitaker P; Peckham D
    Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters.
    Millar BC; McCaughan J; Rendall JC; Downey DG; Moore JE
    J Clin Pharm Ther; 2018 Feb; 43(1):92-100. PubMed ID: 29293275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral anti-pseudomonal antibiotics for cystic fibrosis.
    Remmington T; Jahnke N; Harkensee C
    Cochrane Database Syst Rev; 2013 Oct; (10):CD005405. PubMed ID: 24170644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature Review and Network Meta-analysis.
    Elborn JS; Vataire AL; Fukushima A; Aballea S; Khemiri A; Moore C; Medic G; Hemels ME
    Clin Ther; 2016 Oct; 38(10):2204-2226. PubMed ID: 27692977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis.
    Ren CL; Konstan MW; Yegin A; Rasouliyan L; Trzaskoma B; Morgan WJ; Regelmann W;
    J Cyst Fibros; 2012 Jul; 11(4):293-9. PubMed ID: 22445849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.